These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 25347174)

  • 1. [Fampridine and multiple sclerosis].
    Mathiesen HK; Sørensen PS
    Ugeskr Laeger; 2014 Jan; 176(3A):V06130416. PubMed ID: 25347174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-life experience with fampridine (Fampyra®) for patients with multiple sclerosis and gait disorders.
    Fragoso YD; Adoni T; Alves-Leon SV; Apostolos-Pereira SL; Barreira AA; Brooks JB; Claudino R; Correa EC; Ferreira ML; Finkelsztejn A; Finkelsztejn J; da Gama PD; Goncalves MV; Guerreiro CT; da Cunha Matta AP; Marques VD; Rizo Morales R; Parolin MF; de Castro Ribeiro M; Ribeiro TA; Ruocco HH; Sato H; Scherpenhuijzen S; Siquineli F; de Carvalho Sousa NA; Varela DL; Tauil CB; Winckler TC
    NeuroRehabilitation; 2016 Jun; 39(2):301-4. PubMed ID: 27372365
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prolonged-release fampridine improves walking in a proportion of patients with multiple sclerosis.
    Mathiesen HK; Sorensen PS
    Expert Rev Neurother; 2013 Dec; 13(12):1309-17. PubMed ID: 24236901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Central motor conduction time may predict response to fampridine in patients with multiple sclerosis.
    Zeller D; Reiners K; Bräuninger S; Buttmann M
    J Neurol Neurosurg Psychiatry; 2014 Jun; 85(6):707-9. PubMed ID: 24357684
    [No Abstract]   [Full Text] [Related]  

  • 5. Fampridine response in MS patients with gait impairment in a real-world setting: Need for new response criteria?
    Rodriguez-Leal FA; Haase R; Thomas K; Eisele JC; Proschmann U; Schultheiss T; Kern R; Ziemssen T
    Mult Scler; 2018 Sep; 24(10):1337-1346. PubMed ID: 28741976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical response and tolerability of fampridine in clinical practice.
    Costa-Arpín E; Pato A; Rodríguez-Regal A; Midaglia L; Yáñez R; Muñoz D; Lorenzo JR; Amigo C; Prieto JM
    Neurodegener Dis Manag; 2016 Apr; 6(2):99-105. PubMed ID: 27032814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial.
    Goodman AD; Brown TR; Krupp LB; Schapiro RT; Schwid SR; Cohen R; Marinucci LN; Blight AR;
    Lancet; 2009 Feb; 373(9665):732-8. PubMed ID: 19249634
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prolonged-release fampridine in multiple sclerosis: Improved ambulation effected by changes in walking pattern.
    Zörner B; Filli L; Reuter K; Kapitza S; Lörincz L; Sutter T; Weller D; Farkas M; Easthope CS; Czaplinski A; Weller M; Linnebank M
    Mult Scler; 2016 Oct; 22(11):1463-1475. PubMed ID: 26762672
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Fampridine-PR (prolonged released 4-aminopyridine) on the manual functions of patients with Multiple Sclerosis.
    Savin Z; Lejbkowicz I; Glass-Marmor L; Lavi I; Rosenblum S; Miller A
    J Neurol Sci; 2016 Jan; 360():102-9. PubMed ID: 26723984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sustained release oral fampridine in the treatment of multiple sclerosis.
    Kachuck NJ
    Expert Opin Pharmacother; 2009 Aug; 10(12):2025-35. PubMed ID: 19586420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fampridine and real-life walking in multiple sclerosis: Low predictive value of clinical test for habitual short-term changes.
    Stellmann JP; Jlussi M; Neuhaus A; Lederer C; Daumer M; Heesen C
    J Neurol Sci; 2016 Sep; 368():318-25. PubMed ID: 27538657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predicting responsiveness to fampridine in gait-impaired patients with multiple sclerosis.
    Filli L; Werner J; Beyer G; Reuter K; Petersen JA; Weller M; Zörner B; Linnebank M
    Eur J Neurol; 2019 Feb; 26(2):281-289. PubMed ID: 30171655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiple Sclerosis and Clinical Gait Analysis before and after Fampridine: A Systematic Review.
    Lecat M; Decavel P; Magnin E; Lucas B; Gremeaux V; Sagawa Y
    Eur Neurol; 2017; 78(5-6):272-286. PubMed ID: 28992626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fampridine: Long-term benefits in walking in multiple sclerosis.
    Bennett SE
    Neurology; 2017 Feb; 88(9):818-819. PubMed ID: 28148627
    [No Abstract]   [Full Text] [Related]  

  • 15. Effects of dalfampridine on multi-dimensional aspects of gait and dexterity in multiple sclerosis among timed walk responders and non-responders.
    Lo AC; Ruiz JA; Koenig CM; Anderson BM; Olson KM; Triche EW
    J Neurol Sci; 2015 Sep; 356(1-2):77-82. PubMed ID: 26139339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improving function: a new treatment era for multiple sclerosis?
    Thompson A; Polman C
    Lancet; 2009 Feb; 373(9665):697-8. PubMed ID: 19249614
    [No Abstract]   [Full Text] [Related]  

  • 17. Pharmacology and clinical efficacy of dalfampridine for treating multiple sclerosis.
    Lugaresi A
    Expert Opin Drug Metab Toxicol; 2015 Feb; 11(2):295-306. PubMed ID: 25510833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A guide to treating gait impairment with prolonged-release fampridine (Fampyra
    Ramió-Torrentà L; Álvarez-Cermeño JC; Arroyo R; Casanova-Estruch B; Fernández O; García-Merino JA; Hernández MA; Izquierdo G; Martínez-Yélamos S; Meca J; Moral E; Olascoaga J; Prieto JM; Saiz A
    Neurologia (Engl Ed); 2018 Jun; 33(5):327-337. PubMed ID: 26873645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical overview of dalfampridine: an agent with a novel mechanism of action to help with gait disturbances.
    Egeberg MD; Oh CY; Bainbridge JL
    Clin Ther; 2012 Nov; 34(11):2185-94. PubMed ID: 23123001
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of fampridine for walking disability in multiple sclerosis.
    Arpín EC
    Neurodegener Dis Manag; 2020 Oct; 10(5):277-287. PubMed ID: 32762492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.